Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
3. InterMune Announces Issuance of U.S. Patent for ITMN-191
4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. InterMune to Release Third Quarter 2008 Financial Results on November 6
10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... compliance, quality systems, analytical testing, education and consulting services for the medical ... medical device products/processes development, design control, validation, quality assurance and regulatory compliance. ...
(Date:9/2/2015)... Sep. 02, 2015 Research ... of Jain PharmaBiotech,s new report "Gene Therapy - ... The markets for gene therapy are difficult to ... product and it is marketed in China ... for the years 2014-2024. The estimates are based on ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International ... recognising ,outstanding, science that uses its patented antibody. ... novel prostate cancer diagnostic test known as MiCheck® next ... out the peer-reviewed Australian Museum Eureka Science Prize for ... This prize is awarded for ground breaking research that ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... der Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben ... internationalen vom Rare Genomics Institute. Biovista ... von Medikamenten für die Behandlung anderer Krankheiten als ... Steven Laffoon und sein Team bei ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... GeneLink BioSciences, Inc. (OTC Bulletin Board: ... announced that it ranked number 62 on Technology Fast ... fastest growing technology, media, telecommunications, life sciences and clean ... percentage of fiscal year growth during the period from ...
... -- DALLAS, October 25, 2010 ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Oct. 22 Trius Therapeutics, Inc. (Nasdaq: TSRX ... at Trius Therapeutics, will present "Innovative Antibacterial Drugs by Design; ... event taking place on October 26, 2010 from 5:30-9:30 p.m. ... available at http://sdbn.org/october . About ...
Cached Biology Technology:GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 2MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 2MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 3MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 4MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 5MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 6MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 7MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 8MarketsandMarkets New Report - Global Ophthalmology Drugs & Devices Market 9
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... warming in the upper subtropical oceans of the Southern ... cooling trends to ocean circulation changes induced by global ... Northern Hemisphere from human activity. The research, by ... published today in Scientific Reports . Mr ...
... DETROIT Wayne State University researchers announced today a $25,000 ... strategic plan for a field-based water research center. Known ... and Training the center will focus on the development ... Isle along the Huron-to-Erie corridor, a binational body of water ...
... , July 23, 2013   Neurotechnology , a provider ... of NCheck Bio Attendance 2.0 , an end-user ... NCheck uses biometric fingerprint and face identification to track ... summary time and generates printable reports. The flexibility of ...
Cached Biology News:Rapid upper ocean warming linked to declining aerosols 2Wayne State receives NSF grant to develop plan for field-based water research center 2Neurotechnology Announces NCheck Bio Attendance 2.0 Biometric Time and Attendance Software 2Neurotechnology Announces NCheck Bio Attendance 2.0 Biometric Time and Attendance Software 3
Normal canine serum collected from healthy normal canines....
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Biology Products: